BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8391188)

  • 1. Cell phenotype-dependent control of Epstein-Barr virus latent membrane protein 1 gene regulatory sequences.
    Fåhraeus R; Jansson A; Sjöblom A; Nilsson T; Klein G; Rymo L
    Virology; 1993 Jul; 195(1):71-80. PubMed ID: 8391188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral and cellular factors influence the activity of the Epstein-Barr virus BCR2 and BWR1 promoters in cells of different phenotype.
    Nilsson T; Sjöblom A; Masucci MG; Rymo L
    Virology; 1993 Apr; 193(2):774-85. PubMed ID: 8384755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of Epstein-Barr virus-encoded latent membrane protein by human herpesvirus 6 superinfection of EBV-carrying Burkitt lymphoma cells.
    Cuomo L; Trivedi P; de Grazia U; Calogero A; D'Onofrio M; Yang W; Frati L; Faggioni A; Rymo L; Ragona G
    J Med Virol; 1998 Jul; 55(3):219-26. PubMed ID: 9624610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transient expression of the Epstein-Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis.
    Peng M; Lundgren E
    Oncogene; 1992 Sep; 7(9):1775-82. PubMed ID: 1354347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytostatic effect of Epstein-Barr virus latent membrane protein-1 analyzed using tetracycline-regulated expression in B cell lines.
    Floettmann JE; Ward K; Rickinson AB; Rowe M
    Virology; 1996 Sep; 223(1):29-40. PubMed ID: 8806537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct patterns of viral antigen expression in Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus coinfected body-cavity-based lymphoma cell lines: potential switches in latent gene expression due to coinfection.
    Callahan J; Pai S; Cotter M; Robertson ES
    Virology; 1999 Sep; 262(1):18-30. PubMed ID: 10489337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell phenotype-dependent splicing reflecting differential promoter usage for EBNA transcripts in EBV-carrying cells.
    Hu LF; Chen F; Altiok E; Winberg G; Klein G; Ernberg I
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():248-60. PubMed ID: 10895161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transient expression of the Epstein-Barr virus LMP1 gene in B-cell chronic lymphocytic leukemia cells, T cells, and hematopoietic cell lines: cell-type-independent-induction of CD23, CD21, and ICAM-1.
    Peng M; Lundgren E
    Leukemia; 1993 Jan; 7(1):104-12. PubMed ID: 8093369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional analysis of the mutated Epstein-Barr virus oncoprotein LMP1(69del): implications for a new role of naturally occurring LMP1 variants.
    Larcher C; Bernhard D; Schaadt E; Adler B; Ausserlechner MJ; Mitterer M; Huemer HP
    Haematologica; 2003 Dec; 88(12):1324-35. PubMed ID: 14687985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PU box-binding transcription factors and a POU domain protein cooperate in the Epstein-Barr virus (EBV) nuclear antigen 2-induced transactivation of the EBV latent membrane protein 1 promoter.
    Sjöblom A; Jansson A; Yang W; Laín S; Nilsson T; Rymo L
    J Gen Virol; 1995 Nov; 76 ( Pt 11)():2679-92. PubMed ID: 7595375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Domains of the Epstein-Barr virus nuclear antigen 2 (EBNA2) involved in the transactivation of the latent membrane protein 1 and the EBNA Cp promoters.
    Sjöblom A; Nerstedt A; Jansson A; Rymo L
    J Gen Virol; 1995 Nov; 76 ( Pt 11)():2669-78. PubMed ID: 7595374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in the immunogenicity of latent membrane protein 1 (LMP1) encoded by Epstein-Barr virus genomes derived from LMP1-positive and -negative nasopharyngeal carcinoma.
    Hu L; Troyanovsky B; Zhang X; Trivedi P; Ernberg I; Klein G
    Cancer Res; 2000 Oct; 60(19):5589-93. PubMed ID: 11034108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense to Epstein Barr Virus-encoded LMP1 does not affect the transcription of viral and cellular proliferation-related genes, but induces phenotypic effects on EBV-transformed B lymphocytes.
    Masciarelli S; Mattioli B; Galletti R; Samoggia P; Chichiarelli S; Mearini G; Mattia E
    Oncogene; 2002 Jun; 21(26):4166-70. PubMed ID: 12037673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of a consensus AP-2 regulatory sequence within the Epstein-Barr virus LMP1 promoter in EBNA2 mediated transactivation.
    Jansson A; Johansson P; Yang W; Palmqvist L; Sjöblom-Hallén A; Rymo L
    Virus Genes; 2007 Oct; 35(2):203-14. PubMed ID: 17546492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr Virus EBNA-2 gene expression enhances lymphotoxin production by B lymphocytes.
    McClain K; Estrov Z; Raju U; Kelley PK; Aggarwal BB
    Methods; 1997 Jan; 11(1):83-7. PubMed ID: 8990093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation of the human interleukin 10 promoter. Characterization of the promoter activity in Burkitt's lymphoma cell lines.
    Kube D; Platzer C; von Knethen A; Straub H; Bohlen H; Hafner M; Tesch H
    Cytokine; 1995 Jan; 7(1):1-7. PubMed ID: 7749063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the LMP1 oncoprotein in the EBV negative Hodgkin's disease cell line L-428 is associated with Reed-Sternberg cell morphology.
    Knecht H; McQuain C; Martin J; Rothenberger S; Drexler HG; Berger C; Bachmann E; Kittler EL; Odermatt BF; Quesenberry PJ
    Oncogene; 1996 Sep; 13(5):947-53. PubMed ID: 8806684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Latent membrane protein 1 is critical for efficient growth transformation of human B cells by epstein-barr virus.
    Dirmeier U; Neuhierl B; Kilger E; Reisbach G; Sandberg ML; Hammerschmidt W
    Cancer Res; 2003 Jun; 63(11):2982-9. PubMed ID: 12782607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus (EBV) infection in infectious mononucleosis: virus latency, replication and phenotype of EBV-infected cells.
    Niedobitek G; Agathanggelou A; Herbst H; Whitehead L; Wright DH; Young LS
    J Pathol; 1997 Jun; 182(2):151-9. PubMed ID: 9274524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to cAMP levels of the Epstein-Barr virus EBNA2-inducible LMP1 oncogene and EBNA2 inhibition of a PP1-like activity.
    Fåhraeus R; Palmqvist L; Nerdstedt A; Farzad S; Rymo L; Laín S
    EMBO J; 1994 Dec; 13(24):6041-51. PubMed ID: 7813442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.